MAO/DETECTION OF ANTIBODIES AND PROTEINS

MAO/抗体和蛋白质的检测

• 批准号: 2879677
• 负责人: RONALD WARREN
• 金额: --
• 依托单位: SRA TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-09-30 至 2000-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2879677
• 关键词: AIDS vaccines; Macaca; active immunization; human immunodeficiency virus; simian immunodeficiency virus; technology /technique development

The HIV Preclinical Vaccine Development Master Agreement Program was initiated to enable the NIAID to provide resources to accelerate the development of promising vaccine approaches. Under this program, a series of vaccine studies have been initiated to evaluate candidate and prototype AIDS vaccines in nonhuman primates. These studies are designed to obtain more information about the efficacy and optimum presentation of candidate HIV vaccines that are in human Phase I clinical trials or proposed for such trials as well as prototype SIV vaccines of the same type as these HIV vaccines. Other vaccine studies will evaluate prototype HIV or SIV vaccines that offer novel presentation systems, may be capable of eliciting broadly cross-reactive immune responses, or have shown promising preliminary results. NIAID has initiated collaborative arrangements with researchers who have agreed to provide HIV and SIV vaccines for immunization of nonhuman primates. In all of the vaccine studies, the nonhuman primates will be challenged after immunization to determine if protection from infection or from disease can be obtained. The contractors in Category E of the Master Agreement Program, including the contractor listed above, will provide the laboratory support for these various vaccine studies. The laboratory support work is divided into two parts. Part A pertains to animals immunized with HIV vaccines and challenged with SHIV, and Part B assays pertain to animals immunized with SIV vaccines and challenged with SIV. In all cases assays will be performed such as ELISA and Western Blots to assess the humoral immune responses of immunized macaques. Virus isolations such as co-culture and limiting dilution will be performed to determine if virus infection has occurred after virus challenge. The Category E contractors will maintain a test results database for each study, and will transfer data electronically to the AIDS Vaccine Evaluation Group Statistical and Coordinating Center. In addition, the Category E contractors will provide facilities and equipment to conduct biosafety level 2 or 3 laboratory work.

HIV临床前疫苗开发主协议计划 发起的目的是使 NIAID 能够提供资源来加速 开发有前景的疫苗方法。根据该计划，一系列 疫苗研究已启动以评估候选疫苗和 非人类灵长类动物的艾滋病疫苗原型。这些研究旨在 获得有关功效和最佳呈现的更多信息 处于人体 I 期临床试验的候选 HIV 疫苗或 提议进行此类试验以及相同的 SIV 疫苗原型 类型如这些艾滋病毒疫苗。其他疫苗研究将评估原型 提供新颖呈现系统的 HIV 或 SIV 疫苗可能能够 引发广泛的交叉反应性免疫反应，或已表明 有希望的初步结果。 NIAID 已发起合作 与同意提供 HIV 和 SIV 的研究人员进行安排 用于非人灵长类动物免疫的疫苗。在所有疫苗中 研究表明，非人类灵长类动物在免疫接种后将面临挑战 确定是否可以获得针对感染或疾病的保护。 主协议计划E类承包商，包括 上述承包商将提供实验室支持 这些不同的疫苗研究。实验室支撑工作分工 分为两部分。 A 部分涉及接种 HIV 疫苗的动物 并受到 SHIV 攻击，B 部分检测涉及免疫动物 接种 SIV 疫苗并接受 SIV 攻击。在所有情况下，检测都会 进行 ELISA 和蛋白质印迹等评估体液免疫 免疫猕猴的反应。病毒分离，例如共培养和 将进行有限稀释以确定病毒感染是否已发生 发生在病毒攻击后。 E 类承包商将维持 每个研究的测试结果数据库，并将传输数据 以电子方式发送给艾滋病疫苗评估小组统计和 协调中心。此外，E 类承包商将提供 进行生物安全二级或三级实验室的设施和设备 工作。